Page 16 - Index

Anxiolytic
Perizam Oral Suspension (Clobazam)
1mg/ml and 2mg/ml
PRODUCT DESCRIPTION
Perizam Oral Suspension (Clobazam)
STRENGTH
1mg/ml and 2mg/ml
PACK SIZE
Both strengths are available as 150ml
INDICATIONS
•
Adults for the short-term symptomatic
treatment (2-4 weeks) only of anxiety
that is severe, disabling or subjecting the
individual to unacceptable distress.
•
In treatment of anxiety states associated
with affective disorders, Perizam must
only be used in conjunction with
adequate treatments for the underlying
disorder.
•
In patients with schizophrenic or
other psychotic illnesses, use of
benzodiazepines is recommended
only for short term symptomatic
management of hyperarousal
and agitation.
Benzodiazepines
do not possess
antipsychotic
properties.
•
Perizam may be used as adjunctive
therapy in epilepsy in adults or children
over 2 years, if standard treatment with
one or more anticonvulsants has failed:
Treatment of simple or complex partial
epilepsy with or without secondary
generalisation and treatment of all types
of generalised epilepsy (tonic/clonic,
myoclonic, absence seizures).
A
S
R
P
B
E
R
R
Y
F
L
A
V
O
U
R
S
U
G
A
R
F
R
E
E
E
T
H
A
N
O
L
O%
F
R
E
E
S
U
I
T
A
B
L
E
V
E
G
E
T
A
F
O
R
S
N
R
I
A
M
A
D
E
I
N
T
H
E
U
K
14
Click here for 
Prescribing Information
REFERENCES: 1. World Health Organisation. Mental Disorders. Available at . https://www.who.int/news-room/fact-sheets/detail/mental-
disorders Accessed December 2023. 2. The king’s Fund February 2012. Available at https://www.kingsfund.org.uk/sites/default/files/field/
field_publication_file/long-term-conditions-mental-health-cost-comorbidities-naylor-feb12.pdf Accessed December 2023. 3. The Five
Year Forward View for Mental Health. Available at https://www.england.nhs.uk/wp-content/uploads/2016/02/Mental-Health-Taskforce-
FYFV-final.pdf Accessed December 2023. 4. Centre for Economic Performance. The London School of Economics and Political Science.
Available at http://cep.lse.ac.uk/pubs/download/special/cepsp26.pdf Accessed December 2023. 5. The Sainsbury Centre for Mental
Health. Policy 8. Mental Health at Work: Developing the business case. Available at: http://www.mentalhealthpromotion.net/resources/
mental_health_at_work_developing_the_business_case.pdf Accessed December 2023. 6. Centre for Medical Health. Available at:
https://www.researchgate.net/publication/308382989_The_economic_and_social_costs_of_mental_health_problems_in_200910
Accessed December 2023. 7. National Collaborating Centre for Mental Health. The Improving Access to Psychological
Therapies (IAPT) Pathway for People with Long-Term Physical Health Conditions and Medically Unexplained Symptoms.
Available at https://www.rcpsych.ac.uk/docs/default-source/improving-care/nccmh/iapt/nccmh-iapt-ltc-full-implementation-guidance.pdf?sfvrsn=
de824ea4_4 Accessed December 2023. 8. BMA Pre ARM briefing paper 2018 Mental Health. 9. NHS England.
Available at https://www.england.nhs.uk/mental-health/taskforce/imp/mh-dashboard/ Accessed December 2023. 10. Mind PDF.
Available at https://www.mind.org.uk/media-a/2958/statistics-facts-2017.pdf Accessed December 2023. 11. Well. Talking therapy as
effective as antidepressants’ study finds. Available at: https://www.nicswell.co.uk/health-news/talking-therapy-as-effective-as-antidepressants-
study-finds Accessed December 2023. 12. Administering medication to older mental health patients. Nursing Times 10 April
2007 13. Wright D. (2002) Medication administration in nursing homes. Nursing Standard. 16, 42, 33-38. 14. Owiti J, Bowers L.
A Literature Review: Refusal of Psychotropic Medication in Acute Inpatient Psychiatric Care. November 2010. Section of Mental
Health Nursing, Institute of Psychiatry, London. 15. Darton K. Making Sense of psychiatric medication. Mind 2016. 16. Managing Your
Medication – Living with Schizophrenia. Available at: https://livingwithschizophreniauk.org/information-sheets/managing-your-medication/
Accessed December 2023. 17. Navarro V. Improving Medication Compliance in Patients with Depression: Use of Orodispersible Tablets. Adv
Ther (2010) 27(11):785-795. 18. Wade AG, Crawford GM, Young D. A survey of patient preferences for a placebo orodispersible tablet. Patient
Preference and Adherence, Dove Press, 19 March 2012. 19. Greenwall R. Medicine Management. Medicines management and older people –
a guide for healthcare professionals. Aug 2017. 20. Stovall JG, Gussak LS. Dysphagia and mental illness: looking Beyond Hysteria and Broadening
the Psychiatric Differential Diagnosis. Prim Care Companion. J Clin Psychiatry 2001; 3(3):143-144. Available at www.ncbi.nlm.nih.gov/pmc/
articles/PMC181177/ Accessed December 2023. 21. Crouse EL, et al. Dysphagia with second-generation antipsychotics: A case report and
review of the literature. The Mental Health Clinician. Geropsych Update/Open Submissions. Vol 7, Iss 2. 22. Bobo WV. Switching Antipsychotics:
Why, When and How? Psychiatric Times. Vol 39, Iss 3. March 14, 2013. 23. Llorca PM. Discussion of prevalence and management of discomfort
when swallowing pills: orodispersible tablets expand treatment options in patients with depression. Therapeutic Delivery (2011) 2(5), 611-
622. 24. Mental Health News 14 March 2018. Available at https://www.dpt.nhs.uk/news/swallowing-awareness-day-dysphagia-and-mental-
health Accessed December 2023. 25. Harris C. How to minimise the effects of dysphagia in people with mental health problems. RCNi.
Available at https://journals.rcni.com/mental-health-practice/how-to-minimise-the-effects-of-dysphagia-in-people-with-mental-health-problems-
mhp.18.7.20.e932 Accessed December 2023. 26. Regan J, Sowman R, Walsh I. Prevalence of Dysphagia in Acute & Community Mental
Health Settings. Dysphagia 2006. Apr;21(2): 95-101. 27. Mencap. Available at https://www.mencap.org.uk/learning-disability-explained/research-
and-statistics/health/mental-health Accessed December 2023. 28. Cooper, S.A., Smiley, E., Morrison, J., Williamson, A., & Allan, L. (2007). Mental
ill-health in adults with intellectual disabilities: Prevalence and associated factors. The British Journal of Psychiatry, 190, 27–35. 29. Robertson J,
Chadwick D, et al. People with intellectual disabilities and dysphagia. Disability and Rehabilitation, 2018. Vol 40, No 11, 1435-1360. 30. Chadwick
DD, Joliffe J. A descriptive investigation of dysphagia in adults with intellectual disabilities. Journal of Intellectual Disability Research. 11 December
2008. 31. RPS. Pharmaceutical issues when crushing, opening or splitting oral dosage forms. June 2011. Available at https://www.rpharms.
com/Portals/0/RPS%20document%20library/Open%20access/Support/toolkit/pharmaceuticalissuesdosageforms-%282%29.pdf Accessed
December 2023. 32. Survey of medicine related care of residents with dysphagia in care homes. The Patients Association. Available at https://
pexlib.net/?84874 Accessed December 2023 33. NEEMMC Guidelines for tablet crushing and administration via enteral feeding tubes.
Medicines Information, Pharmacy Department, Colchester Hospital Foundation University NHS Trust, 2012. 34. Greener M. Wasted medicines
and avoidable adverse reactions: a multibillion pound problem. JME 2006;9 :27-44.